Close Menu

This article has been updated to clarify details of FDA's letter.


NEW YORK (GenomeWeb) – The US Food and Drug Administration has sent a letter to Sure Genomics asking why the company is marketing its SureDNA sequencing test, which collects and analyzes saliva samples and reports disease risk and drug response information to patients, without its clearance.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.